Swiss pharmaceutical group, Helsinn, has announced the launch of the intravenous formulation of AKYNZEO (a fixed combination of fosnetupitant, 235 mg, and palonosetron, 0.25 mg) in the US.
US Flag
This IV formulation in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy received FDA approval last month (April 2018). It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.
The oral form of AKYNZEO was approved by the FDA in 2014 as a fixed combination oral agent for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
“Helsinn’s mission is to help people with cancer get the most out of every day,” commented Giorgio Calderari, Helsinn Group general manager. “We’re delighted that we are now able to make this therapy available in intravenous formulation. This is an important moment for Helsinn, as it allows us to bring an additional option to patients experiencing CINV in highly emetogenic chemotherapy treatment.”
Paul Rittman, chief executive officer of Helsinn Therapeutics, added: “We are delighted to launch the intravenous formulation of AKYNZEO in the US market. One of our top priorities is to further expand the presence of Helsinn in the US in order to help even more people who are suffering from the emetogenic side effects of cancer treatment.”